Cargando…
miR-145-5p Targets Sp1 in Non-Small Cell Lung Cancer Cells and Links to BMI1 Induced Pemetrexed Resistance and Epithelial–Mesenchymal Transition
Pemetrexed is a folic acid inhibitor used as a second-line chemotherapeutic agent for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), which accounts for 85% of lung cancers. However, prolonged treatment with pemetrexed may cause cancer cells to develop resistance....
Autores principales: | Chang, Wen-Wei, Wang, Bing-Yen, Chen, Shih-Hong, Chien, Peng-Ju, Sheu, Gwo-Tarng, Lin, Ching-Hsiung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9741456/ https://www.ncbi.nlm.nih.gov/pubmed/36499676 http://dx.doi.org/10.3390/ijms232315352 |
Ejemplares similares
-
BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness
por: Shen, Huan-Ting, et al.
Publicado: (2020) -
Effect of Folic Acid and Vitamin B(12) on Pemetrexed Antifolate Chemotherapy in Nutrient Lung Cancer Cells
por: Yang, Tsung-Ying, et al.
Publicado: (2013) -
High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase
por: Kuo, Wei-Ting, et al.
Publicado: (2017) -
CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum
por: Hsin, I-Lun, et al.
Publicado: (2020) -
Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer
por: Li, Che-Hsing, et al.
Publicado: (2021)